Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED (4568)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
12:58pVAXART : Announces $5 Million Inavir Revenue Milestone
AQ
04/19DAIICHI SANKYO : Patent Issued for Methods for Producing Optically Active Valeri..
AQ
04/19DAIICHI SANKYO : Reports Outline Clostridium difficile Study Findings from Daiic..
AQ
04/12DAIICHI SANKYO : and DarwinHealth Enter Exclusive Research Collaboration for Nov..
AQ
04/05DAIICHI SANKYO : Moves delhi hc to block sale of fortis to manipal
AQ
04/04DAIICHI SANKYO : Agrees to Modify the Terms of the Settlement Program for U.S. O..
AQ
04/03DAIICHI SANKYO : 65IB) 65IB Drugs, Pharmaceuticals and Hematology related produc..
AQ
04/03DAIICHI SANKYO : $311.9 Million Federal Contract Awarded to Daiichi Sankyo
AQ
04/02DAIICHI SANKYO : moves SEBI to block Fortis-Manipal deal
AQ
03/29DAIICHI SANKYO : Patent Issued for Method for Improving Dissolution of Anticoagu..
AQ
More news
News from SeekingAlpha
04/20Vaxart earns $5M milestone from Daiichi on Inavir sales 
04/04Daiichi teams up with DarwinHealth to identify new cancer targets 
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/09Homology Medicines Files For U.S. IPO 
03/093 THINGS IN BIOTECH, MARCH 8 : A Tale Of 3 New Trials 
Financials ( JPY)
Sales 2018 952 B
EBIT 2018 -
Net income 2018 57 027 M
Finance 2018 338 B
Yield 2018 1,86%
P/E ratio 2018 41,65
P/E ratio 2019 39,98
EV / Sales 2018 2,45x
EV / Sales 2019 2,51x
Capitalization 2 664 B
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 3 245  JPY
Spread / Average Target -14%
EPS Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED25.45%24 750
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571